Quidel Corp.

Quidel is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The company provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel?, QuickVue?, QuickVue+?, Sofia?, Triage?, AmpliVue?, Solana?, Virena?, MicroVue?, Lyra?, FreshCells?, D3?, FastPoint?, ReadyCells?, Super E-Mix?, InflammaDry?, AdenoPlus?, ELVIRA?, ELVIS? and Thyretain?. The company's diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiac immunoassay, specialized diagnostic solutions and molecular diagnostic solutions.
  • TickerQDEL
  • ISINUS74838J1016
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States
 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q R...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia® Q, its latest addition to the Sofia® and Sofia® 2 line of Fluorescent Immunoassay Analyzers (FIA). Sofia Q features a sleek, miniaturized design that reads the same Sofia® SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at Raymond James Human Health Innovation C...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James Human Health Innovation Conference 2021 to be held virtually on Monday, June 21, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 1:20 p.m. Eastern time (10:20 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will d...

QDEL QUIDEL CORP. (Health Care)

QUIDEL sees an upgrade to Slightly Negative thanks to a better star ra...

The independent financial analyst theScreener just awarded an improved star rating to QUIDEL (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date May 25, 2021, the closing price was USD 119.04 and its target price was estimated at USD 70.69.

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at William Blair 41st Annual Growth Stock ...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 41st Annual Growth Stock Conference to be held virtually on Thursday, June 3, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 10:40 a.m. Central time (8:40 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will discuss busi...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Health Canada Approves Quidel’s Sofia® SARS Antigen FIA Test for Scree...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its Sofia® SARS Antigen FIA is the first rapid antigen test to receive authorization from Health Canada for serial testing for the detection of active coronavirus infection in both symptomatic and asymptomatic populations. The Sofia SARS Antigen FIA is a lateral flow immunofluorescent sandwich assay that is used with the Sofia and Sofia 2 instrument intended for the qualitative...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q R...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia® Q, its latest addition to the Sofia® and Sofia® 2 line of Fluorescent Immunoassay Analyzers (FIA). Sofia Q features a sleek, miniaturized design that reads the same Sofia® SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at Raymond James Human Health Innovation C...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James Human Health Innovation Conference 2021 to be held virtually on Monday, June 21, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 1:20 p.m. Eastern time (10:20 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will d...

QDEL QUIDEL CORP. (Health Care)

QUIDEL sees an upgrade to Slightly Negative thanks to a better star ra...

The independent financial analyst theScreener just awarded an improved star rating to QUIDEL (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date May 25, 2021, the closing price was USD 119.04 and its target price was estimated at USD 70.69.

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at William Blair 41st Annual Growth Stock ...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 41st Annual Growth Stock Conference to be held virtually on Thursday, June 3, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 10:40 a.m. Central time (8:40 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will discuss busi...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Health Canada Approves Quidel’s Sofia® SARS Antigen FIA Test for Scree...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its Sofia® SARS Antigen FIA is the first rapid antigen test to receive authorization from Health Canada for serial testing for the detection of active coronavirus infection in both symptomatic and asymptomatic populations. The Sofia SARS Antigen FIA is a lateral flow immunofluorescent sandwich assay that is used with the Sofia and Sofia 2 instrument intended for the qualitative...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q R...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia® Q, its latest addition to the Sofia® and Sofia® 2 line of Fluorescent Immunoassay Analyzers (FIA). Sofia Q features a sleek, miniaturized design that reads the same Sofia® SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at Raymond James Human Health Innovation C...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James Human Health Innovation Conference 2021 to be held virtually on Monday, June 21, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 1:20 p.m. Eastern time (10:20 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will d...

QDEL QUIDEL CORP. (Health Care)

QUIDEL sees an upgrade to Slightly Negative thanks to a better star ra...

The independent financial analyst theScreener just awarded an improved star rating to QUIDEL (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date May 25, 2021, the closing price was USD 119.04 and its target price was estimated at USD 70.69.

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at William Blair 41st Annual Growth Stock ...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 41st Annual Growth Stock Conference to be held virtually on Thursday, June 3, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 10:40 a.m. Central time (8:40 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will discuss busi...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Health Canada Approves Quidel’s Sofia® SARS Antigen FIA Test for Scree...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its Sofia® SARS Antigen FIA is the first rapid antigen test to receive authorization from Health Canada for serial testing for the detection of active coronavirus infection in both symptomatic and asymptomatic populations. The Sofia SARS Antigen FIA is a lateral flow immunofluorescent sandwich assay that is used with the Sofia and Sofia 2 instrument intended for the qualitative...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q R...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia® Q, its latest addition to the Sofia® and Sofia® 2 line of Fluorescent Immunoassay Analyzers (FIA). Sofia Q features a sleek, miniaturized design that reads the same Sofia® SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at Raymond James Human Health Innovation C...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James Human Health Innovation Conference 2021 to be held virtually on Monday, June 21, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 1:20 p.m. Eastern time (10:20 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will d...

QDEL QUIDEL CORP. (Health Care)

QUIDEL sees an upgrade to Slightly Negative thanks to a better star ra...

The independent financial analyst theScreener just awarded an improved star rating to QUIDEL (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date May 25, 2021, the closing price was USD 119.04 and its target price was estimated at USD 70.69.

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at William Blair 41st Annual Growth Stock ...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 41st Annual Growth Stock Conference to be held virtually on Thursday, June 3, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 10:40 a.m. Central time (8:40 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will discuss busi...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Health Canada Approves Quidel’s Sofia® SARS Antigen FIA Test for Scree...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its Sofia® SARS Antigen FIA is the first rapid antigen test to receive authorization from Health Canada for serial testing for the detection of active coronavirus infection in both symptomatic and asymptomatic populations. The Sofia SARS Antigen FIA is a lateral flow immunofluorescent sandwich assay that is used with the Sofia and Sofia 2 instrument intended for the qualitative...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q R...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia® Q, its latest addition to the Sofia® and Sofia® 2 line of Fluorescent Immunoassay Analyzers (FIA). Sofia Q features a sleek, miniaturized design that reads the same Sofia® SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at Raymond James Human Health Innovation C...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James Human Health Innovation Conference 2021 to be held virtually on Monday, June 21, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 1:20 p.m. Eastern time (10:20 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will d...

QDEL QUIDEL CORP. (Health Care)

QUIDEL sees an upgrade to Slightly Negative thanks to a better star ra...

The independent financial analyst theScreener just awarded an improved star rating to QUIDEL (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date May 25, 2021, the closing price was USD 119.04 and its target price was estimated at USD 70.69.

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Quidel to Present Virtually at William Blair 41st Annual Growth Stock ...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 41st Annual Growth Stock Conference to be held virtually on Thursday, June 3, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 10:40 a.m. Central time (8:40 a.m. Pacific time) in a question-and-answer teleconference format. During the presentation, the company will discuss busi...

 PRESS RELEASE
QDEL QUIDEL CORP. (Health Care)

Health Canada Approves Quidel’s Sofia® SARS Antigen FIA Test for Scree...

SAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its Sofia® SARS Antigen FIA is the first rapid antigen test to receive authorization from Health Canada for serial testing for the detection of active coronavirus infection in both symptomatic and asymptomatic populations. The Sofia SARS Antigen FIA is a lateral flow immunofluorescent sandwich assay that is used with the Sofia and Sofia 2 instrument intended for the qualitative...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch